Albumin

ApprovedSmall molecule

LLaboratoire français de Fractionnement et de Biotechnologies

Albumin is one of 295 small molecule programs targeting Ascites. It is currently in Approved.

Indications

Total Trials

Active Trials

294

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

AscitesRecruiting

Cerebral IschemiaNot yet recruiting

Systemic Inflammatory Response SyndromeActive, not recruiting

Liver TransplantActive, not recruiting

Acute-on-Chronic Liver FailureActive, not recruiting

PeritonitisActive, not recruiting

Chronic Liver FailureActive, not recruiting

EncephalopathyActive, not recruiting

Septic ShockCompleted

Acute Kidney InjuryActive, not recruiting

AscitesPhase 3

Recruiting

Cerebral IschemiaPhase 2

Not yet recruiting

Systemic Inflammatory Response SyndromeApproved

Active, not recruiting

Liver TransplantPreclinical

Active, not recruiting

Acute-on-Chronic Liver FailurePreclinical

Active, not recruiting

PeritonitisPreclinical

Active, not recruiting

Chronic Liver FailurePreclinical

Active, not recruiting

EncephalopathyApproved

Active, not recruiting

Septic ShockApproved

Completed

Acute Kidney InjuryPreclinical

Active, not recruiting

Showing 10 of 16 indications

Competition

Competitive Landscape

139 competitors in Efficacy

#DrugCompanyPhaseTrials

Biaxin

AbbVie

Phase 3

4 2

Tivicay

GSK

Phase 3

2 3

Albumin

LLaboratoire français de Fractionnement et de Biotechnologies

Approved

1 4

Paraplatin

AAvyxa

Phase 3

4 5

Lesinurad

EEsperion Therapeutics, Inc.

Phase 3

2 6

Pifeltro

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

1 7

Platelet Rich Plasma

ZZagazig University

Phase 3

5 8

Suraxavir Marboxil

JJiangxi Kvvit Pharmaceutical Co., Ltd.

Phase 3

1 9

Aralen

Sanofi

Preclinical

2 10

Primaquine

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Cirrhosis

NCT06052176

Q1 2027

Phase 2Recruiting

Cirrhosis

NCT06812390

Q2 2027

Phase 2Recruiting

Ascites

NCT05867602

Q4 2027

Phase 3Recruiting

Acute Ischemic Stroke

NCT07263308

Post-ApprovalNot yet recruiting

Volume

NCT05463471

N/ARecruiting

Acute Kidney Injury

NCT06710353

Clinical

Trials by Indication[1]

Cirrhosis12 trials

Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.

Not yet recruiting·IInstitute of Liver and Biliary Sciences, India·N/A·NCT07002827·60 enrolled

Efficacy of Targeted And Response-Guided Albumin Therapy Versus Standard Medical Treatment In Outcomes Of Recurrent Ascites In Patients With Decompensated Cirrhosis.

Unknown status·IInstitute of Liver and Biliary Sciences, India·N/A·NCT04679571·100 enrolled

Midodrine, Octreotide and Albumin: Impact on Renal Function of Patients With Liver Cirrhosis and Renal Failure

Withdrawn·AAnna Cruceta·Phase 2·NCT01587222

Show 9 more trials

Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis

Completed·UUS Department of Veterans Affairs·Phase 4·NCT00108355·29 enrolled

Coagulation Parameters With Albumin in Decompensated Cirrhosis (CoPA-D).

Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT05937048·120 enrolled

Efficacy and Safety of Terlipressin With Albumin Versus Midodrine With Albumin Versus Albumin Alone in Prevention of Paracentesis Induced Circulatory Dysfunction in Cirrhosis

Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT03144713·150 enrolled

Evaluation of Low-dose Albumin and Midodrine Versus Midodrine Alone in Outcome of Recurrent Ascites in Patients With Decompensated Cirrhosis.

Unknown status·IInstitute of Liver and Biliary Sciences, India·N/A·NCT06245590·100 enrolled

Albumin Infusion in Inpatients With Decompensated Cirrhosis

Unknown status·RRuijin Hospital··NCT05719051·564 enrolled

Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites

Recruiting·—·Phase 2·NCT06812390·20 enrolled

Effects of Long Term Albumin 20% Administration in Patients With Cirrhosis and Ascites.

Completed·IInstituto Grifols, S.A.·Phase 4·NCT00968695·33 enrolled

Evaluation of Albumin and Midodrine Versus Albumin Alone in Outcome of Refractory Ascites in Patients With Decompensated Cirrhosis.

Unknown status·IInstitute of Liver and Biliary Sciences, India·N/A·NCT04816240·200 enrolled

Randomized Clinical Trial in Hepatic Encephalopathy to Study Lasting Cognitive Improvement With Intravenous Albumin

Active, not recruiting·HHunter Holmes Mcguire Veteran Affairs Medical Center·Phase 2·NCT06052176·25 enrolled

Volume3 trials

Fresh Frozen Plasma as a Substitute for Albumin in Patients Receiving a Large Volume Paracentesis

Withdrawn·MMontefiore Medical Center·Phase 2·NCT04109144

Fresh Frozen Plasma as a Substitute for Albumin in Patients Receiving a Large Volume Paracentesis

Withdrawn·MMontefiore Medical Center·Phase 4·NCT03202524

Effect of Balanced Saline Solution and Albumin on Volume Expansion in Shock Patients

Not yet recruiting·PPeking Union Medical College Hospital·Phase 4·NCT05463471·500 enrolled

Peritonitis3 trials

Comparison of Standard Dose Versus Once a Day Intravenous Albumin in Spontaneous Bacterial Peritonitis

Completed·—·N/A·NCT02756741·40 enrolled

To Study Efficacy of Albumin in Cirrhosis With Spontaneous Bacterial Peritonitis at Low Risk for AKI Development

Unknown status·IInstitute of Liver and Biliary Sciences, India·N/A·NCT04437810·100 enrolled

To Compare the Efficacy of Carbepenem Versus Carbepenem Plus GM-CSF in Difficult To Treat Spontaneous Bacterial Peritonitis

Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT02468089·146 enrolled

Encephalopathy2 trials

Post Transjugular Intrahepatic Portosystemic Shunt (Tips) Albumine Infusion to Prevent Hepatic Encephalopathy

Completed·UUniversity of Roma La Sapienza·Phase 4·NCT01559519·20 enrolled

Efficacy of Albumin for Acute Encephalopathy in Patients With Cirrhosis

Completed·HHospital Universitari Vall d'Hebron Research Institute·Phase 4·NCT00886925·56 enrolled

Treatment2 trials

IVIG (Gamunex-C) Treatment Study for POTS Subjects

Completed·UUniversity of Texas Southwestern Medical Center·Phase 1/2·NCT03919773·30 enrolled

A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD

Terminated·BBaxalta now part of Shire·Phase 2/3·NCT02956122·1 enrolled

41 more indications

Ascites2 trials

Midodrine and Albumin in Patients With Refractory Ascites

Unknown status·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 3·NCT04621617·114 enrolled

Clinical Efficacy of High-dose Albumin Administration Versus Standard Dose in Patients With Advanced Cirrhosis: Open Label Randomized Clinical Trial

Recruiting·BBaylor College of Medicine·Phase 2·NCT05867602·100 enrolled

Cardiac Surgery2 trials

Albumin Administration and Outcomes in Cardiac Surgery

Completed·VVanderbilt University··NCT02878733·6,249 enrolled

Albumin in Cardiac Surgery

Completed·HHelsinki University Central Hospital·Phase 4·NCT02560519·1,386 enrolled

Acute Kidney Injury2 trials

Comparison of Safety and Efficacy of Tailored Versus Fixed Dose Albumin for the Management of Patients With Cirrhosis and Sepsis Associated Acute Kidney Injury

Not yet recruiting·IInstitute of Liver and Biliary Sciences, India·N/A·NCT06809088·100 enrolled

The Effect of Preoperative Albumin Administration on Postoperative Acute Kidney Injury in Pediatric Patients With Hypoalbuminemia Undergoing Cardiac Surgery

Recruiting·SSeoul National University Hospital·N/A·NCT06710353·190 enrolled

Liver Transplant2 trials

Effect of Midodrine and Albumine in the Prevention of Complications in Cirrhotic Patients Awaiting Liver Transplantation

Completed·HHospital Clinic of Barcelona·Phase 4·NCT00839358·199 enrolled

Post-Operative Use of Salt Poor Albumin Solution in Resuscitation of Orthotopic Liver Transplant

Unknown status·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·N/A·NCT00842803·100 enrolled

Septic Shock2 trials

Early Albumin Resuscitation During Septic Shock

Completed·LLaboratoire français de Fractionnement et de Biotechnologies·Phase 4·NCT00327704·794 enrolled

ALBumin Italian Outcome Septic Shock-BALANCED Trial (ALBIOSS-BALANCED)

Completed·FFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico·Phase 3·NCT03654001·1,319 enrolled

Fusion Rate2 trials

Importance of the Infusion Rate for the Plasma Expanding Effect of 5% Albumin in the Septic Patient

Unknown status·—·Phase 4·NCT03153306·60 enrolled

Infusion Rate and Volume Kinetics for Hyperoncotic Albumine in Healthy Subjects

Completed·UUniversity Hospital, Linkoeping·Phase 4·NCT03453320·12 enrolled

Acute-on-Chronic Liver Failure2 trials

Efficacy of Early Terlipressin Plus Albumin Therapy in Comparison to Standard Treatment for HRS-AKI in Acute-on-chronic Liver Failure.

Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT04416282·70 enrolled

Incidence And Outcome Of Paracentesis Induced Circulatory Dysfunction In Acute-On-Chronic Liver Failure.

Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT02467348·80 enrolled

Effectiveness1 trial

Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children

Withdrawn·HHospices Civils de Lyon·Phase 4·NCT02899702

Diabetes Mellitus1 trial

A Pilot Study of Hemin Therapy for Gastroparesis (Diabetes Mellitus)

Completed·MMayo Clinic·Phase 2·NCT01206582·20 enrolled

Sepsis1 trial

Lactated Ringer Versus Albumin in Early Sepsis Therapy

Completed·UUniversity of Sao Paulo·Phase 3·NCT01337934·360 enrolled

Pediatric1 trial

Albumin vs. Plasma for PEdiAtric pRiming Trial

Completed·IIRCCS Policlinico S. Donato·Phase 4·NCT02738190·80 enrolled

Complication1 trial

Midodrine Plus Albumin Versus Midodrine Alone to Prevent Cirrhosis Related Complications in Children With Cirrhosis and Ascites

Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT06091345·61 enrolled

Amyotrophic Lateral Sclerosis1 trial

Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral Sclerosis

Completed·IInstituto Grifols, S.A.·Phase 2·NCT02479802·13 enrolled

Systemic Sclerosis1 trial

AIMSPRO in Established Diffuse Cutaneous Systemic Sclerosis

Unknown status·DDaval International Limited·Phase 2·NCT00769028·20 enrolled

Intracerebral Hemorrhage1 trial

Albumin for Intracerebral Hemorrhage Intervention

Terminated·GGeorgetown University·Phase 2·NCT00990509·14 enrolled

Chronic Liver Failure1 trial

Efficacy of Albumin Therapy With Standard Medical Treatment (SMT) as Compared to Standard Medical Treatment (SMT) in Improving Patient Survival and Immune Modulation in Patients With Acute on Chronic Liver Failure (ASIA Trial).

Unknown status·IInstitute of Liver and Biliary Sciences, India·N/A·NCT03754400·200 enrolled

Myopathy1 trial

Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial)

Withdrawn·UUniversity of Washington·Phase 2·NCT04450654

Stroke1 trial

Intra-arterial Albumin Infusion After Endovascular Therapy for Stroke Patients

Completed·TTianjin Huanhu Hospital·Phase 1·NCT05953623·57 enrolled

Cesarean Delivery1 trial

Transthoracic Echocardiographic Monitoring of Cardiac Output Effects of Colloid Preload and Crystalloid Coload During Cesarean Delivery Under Spinal Anesthesia

Completed·SSameh Fathy·N/A·NCT06654687·162 enrolled

Ischemic stroke1 trial

Albumin in Acute Ischemic Stroke Trial

Terminated·UUniversity of Miami·Phase 3·NCT00235495·841 enrolled

Infusion1 trial

To Study The Incidence And Outcome Of Paracentesis Induced Circulatory Dysfunction in Decompensated Cirrhotics Undergoing Less Than 5 Litres Of Ascitic Fluid Tap With Or Without Albumin Infusion.

Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT02467322·80 enrolled

Efficacy1 trial

Efficacy of Albumin Plus Midodrine v/s Albumin Alone in Reducing Incidence of Paracentesis Induced Circulatory Dysfunctions in ACLF Patients.

Unknown status·IInstitute of Liver and Biliary Sciences, India·N/A·NCT04474262·150 enrolled

Efficacy and Safety1 trial

Study on Efficacy and Safety of Human Albumin in Burn Shock Recovery

Completed·SSecond Affiliated Hospital, School of Medicine, Zhejiang University··NCT04928859·364 enrolled

Pancreaticoduodenectomy1 trial

Comparison of Hemodynamic Effects of Two Colloid Therapies in Post-operative Patients Undergoing Pancreaticoduodenectomy

Completed·—·Phase 3·NCT01758172·100 enrolled

Intravenous1 trial

Efficacy of IntraVenous ImmunoGlobulins in Toxic Shock Syndromes: a Paediatric Pilot Study

Completed·HHospices Civils de Lyon·Phase 2·NCT02219165·30 enrolled

Type 2 Diabetes Mellitus1 trial

Safety and Efficacy of OCN19-overexpressed Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Refractory Type 2 Diabetes Mellitus

Recruiting·LLu jin ，MD·Phase 2·NCT06727721·10 enrolled

Randomized Controlled Trial1 trial

Furosemide and Albumin for Diuresis of Edema: A Pilot Randomized Controlled Trial

Completed·HHamilton Health Sciences Corporation·Phase 3·NCT02055872·46 enrolled

Hemorrhagic Shock1 trial

Initial Resuscitation With Albumin in Hemorrhagic Shock to Reduce Positive Fluid Balance

Unknown status·SSeoul National University Hospital·N/A·NCT06111261·36 enrolled

Cerebral ischemia1 trial

Modulation of Cerebral Ischemia by Albumin

Not yet recruiting·UUniversity Hospital Hradec Kralove·Phase 2·NCT07415655·100 enrolled

Hepatocellular Carcinoma1 trial

Albumin for Hepatocellular Carcinoma

Unknown status·GGuangxi Medical University·Phase 3·NCT03974074·200 enrolled

Hepatorenal Syndrome1 trial

Angiotensin 2 for Hepatorenal Syndrome

Withdrawn·UUniversity of California, Los Angeles·Phase 2·NCT04048707

Systemic Inflammatory Response Syndrome1 trial

Biseko Versus Albumin in Systemic Inflammatory Response Syndrome (SIRS) Patients

Completed·MMedical University of Vienna·Phase 4·NCT00708747·40 enrolled

Connective Tissue Graft1 trial

A Clinical Comparison of Connective Tissue Graft and Alb-PRF for Rebuilding Interdental Papilla

Not yet recruiting·Sshaimaa hamdy·Phase 3·NCT07139392·30 enrolled

SMA1 trial

Plasma Exchange With Albumin in AMN Patients

Completed·—·Phase 2/3·NCT04303416·5 enrolled

Prevention1 trial

The INFECIR-2 Albumin Prevention Study

Terminated·EEASL - CLIF Consortium·Phase 4·NCT02034279·136 enrolled

Safety and Efficacy1 trial

To Study the Safety and Efficacy of Midodrine With Albumin Versus Albumin Alone in Hepatic Hydrothorax

Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT03645642·8 enrolled

Acute Variceal Bleeding1 trial

Albumin in Acute Variceal Bleeding

Not yet recruiting·KKing George's Medical University·Phase 3·NCT07395141·60 enrolled

Double-blind1 trial

Low-dose Albumin Solution in SBP: a Randomized Double-blind Pilot Study

Unknown status·HHospital de Clinicas de Porto Alegre·Phase 2·NCT00852800·43 enrolled

Critically Ill Patients1 trial

Effects of Fluid Balance Control in Critically Ill Patients

Completed·—·N/A·NCT02765009·1,411 enrolled

Acute Ischemic Stroke1 trial

Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2

Recruiting·CCapital Medical University·Phase 3·NCT07263308·1,192 enrolled

Intensive Care1 trial

The Intensive Care Platform Trial (INCEPT)

Recruiting·AAnders Perner·Approved·NCT06667999·10,000 enrolled

Regulatory

FDA Approval Timeline[4]

Oct 14, 1977

MEGATOPE

NDA BLA017837

Oct 14, 1977

MEGATOPE

NDA BLA017837

Oct 14, 1977

MEGATOPE

NDA BLA017837

Oct 14, 1977

MEGATOPE

NDA BLA017837

Oct 14, 1977

MEGATOPE

NDA BLA017837

Nov 16, 1978

MEGATOPE

NDA BLA017837

Aug 17, 1981

MEGATOPE

NDA BLA017837

Oct 4, 1983

MEGATOPE

NDA BLA017837

Oct 25, 1983

MEGATOPE

NDA BLA017837

Jan 22, 1985

MEGATOPE

NDA BLA017837

Sep 30, 1985

MEGATOPE

NDA BLA017837

Dec 30, 1987

TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT

NDA BLA017881

May 21, 1996

MEGATOPE

NDA BLA017837

Dec 31, 1997

OPTISON

NDA NDA020899

Feb 1, 1999

OPTISON

NDA NDA020899

Apr 2, 1999

TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT

NDA BLA017881

Apr 2, 1999

TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT

NDA BLA017881

May 6, 1999

OPTISON

NDA NDA020899

Feb 4, 2000

OPTISON

NDA NDA020899

Mar 14, 2000

OPTISON

NDA NDA020899

Dec 18, 2000

OPTISON

NDA NDA020899

May 10, 2002

OPTISON

NDA NDA020899

Jul 23, 2002

TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT

NDA BLA017881

Nov 8, 2007

OPTISON

NDA NDA020899

Jun 6, 2008

OPTISON

NDA NDA020899

Oct 17, 2008

TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT

NDA BLA017881

Jun 5, 2009

TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT

NDA BLA017881

Sep 23, 2011

TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT

NDA BLA017881

Aug 17, 2012

OPTISON

NDA NDA020899

Mar 4, 2013

TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT

NDA BLA017881

Nov 15, 2013

OPTISON

NDA NDA020899

May 11, 2015

TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT

NDA BLA017881

Mar 1, 2016

TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT

NDA BLA017881

Apr 15, 2016

OPTISON

NDA NDA020899

Jun 9, 2016

TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT

NDA BLA017881

Sep 16, 2016

OPTISON

NDA NDA020899

Sep 16, 2016

OPTISON

NDA NDA020899

Oct 20, 2017

TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT

NDA BLA017881

Mar 20, 2020

PULMOTECH MAA

NDA BLA210089

Sep 1, 2021

OPTISON

NDA NDA020899

Sep 16, 2021

OPTISON

NDA NDA020899

Jul 27, 2022

PACLITAXEL

NDA NDA211875

Aug 25, 2023

MEGATOPE

NDA BLA017837

Aug 25, 2023

PULMOTECH MAA

NDA BLA210089

Dec 1, 2023

TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT

NDA BLA017881

May 9, 2025

OPTISON

NDA NDA020899

May 15, 2025

PACLITAXEL

NDA ANDA216355

Sources

References

[1]
ClinicalTrials.gov — 70 trial records for Albumin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Albumin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Albumin. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA ANDA216355). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Laboratoire français de Fractionnement et de Biotechnologies company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: LLaboratoire français de Fractionnement et de Biotechnologies

Albumin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Q4 2027

Trials by Indication[1]

Cirrhosis12 trials

Volume3 trials

Peritonitis3 trials

Encephalopathy2 trials

Treatment2 trials

Ascites2 trials

Cardiac Surgery2 trials

Acute Kidney Injury2 trials

Liver Transplant2 trials

Septic Shock2 trials

Fusion Rate2 trials

Acute-on-Chronic Liver Failure2 trials

Effectiveness1 trial

Diabetes Mellitus1 trial

Sepsis1 trial

Pediatric1 trial

Complication1 trial

Amyotrophic Lateral Sclerosis1 trial

Systemic Sclerosis1 trial

Intracerebral Hemorrhage1 trial

Chronic Liver Failure1 trial

Myopathy1 trial

Stroke1 trial

Cesarean Delivery1 trial

Ischemic stroke1 trial

Infusion1 trial

Efficacy1 trial

Efficacy and Safety1 trial

Pancreaticoduodenectomy1 trial

Intravenous1 trial

Type 2 Diabetes Mellitus1 trial

Randomized Controlled Trial1 trial

Hemorrhagic Shock1 trial

Cerebral ischemia1 trial

Hepatocellular Carcinoma1 trial

Hepatorenal Syndrome1 trial

Systemic Inflammatory Response Syndrome1 trial

Connective Tissue Graft1 trial

SMA1 trial

Prevention1 trial

Safety and Efficacy1 trial

Acute Variceal Bleeding1 trial

Double-blind1 trial

Critically Ill Patients1 trial

Acute Ischemic Stroke1 trial

Intensive Care1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News